相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment
Edward V. Loftus et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)
Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study
Mirabella Zhao et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North
B Siegmund et al.
Journal of Crohns & Colitis (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
Juan S. Lasa et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID
Gilles Boschetti et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Silvio Danese et al.
LANCET (2022)
Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis
Keiichi Haga et al.
BIOMEDICINES (2022)
Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial
Masakazu Nagahori et al.
DIGESTION (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies
Charlie W. Lees et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
CINeMA: An approach for assessing confidence in the results of a network meta-analysis
Adriani Nikolakopoulou et al.
PLOS MEDICINE (2020)
Ulcerative colitis
Taku Kobayashi et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
Stephen Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study
G. D'Haens et al.
JOURNAL OF CROHNS & COLITIS (2019)
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials
Stephen Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2019)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
Christopher Andrew Lamb et al.
GUT (2019)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses
Audrey Beliveau et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis
Shannon E. Telesco et al.
GASTROENTEROLOGY (2018)
Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis
Cristina Trigo-Vicente et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2018)
Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)
Toshifumi Hibi et al.
JOURNAL OF GASTROENTEROLOGY (2017)
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis
Taku Kobayashi et al.
JOURNAL OF GASTROENTEROLOGY (2016)
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis
P. Rutgeerts et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis
Silvio Danese et al.
ANNALS OF INTERNAL MEDICINE (2014)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: An indirect treatment comparison meta-analysis
Kristian Thorlund et al.
JOURNAL OF CROHNS & COLITIS (2014)
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
Yasuo Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Ole Haagen Nielsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
Georgia Salanti
RESEARCH SYNTHESIS METHODS (2012)
Automating network meta-analysis
Gert van Valkenhoef et al.
RESEARCH SYNTHESIS METHODS (2012)
Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy
J. R. Gray et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Open-Label Study of Adalimumab in Patients with Ulcerative Colitis Including Those with Prior Loss of Response or Intolerance to Infliximab
Waqqas Afif et al.
INFLAMMATORY BOWEL DISEASES (2009)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study
Laurent Peyrin-Biroulet et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis:: a randomised controlled trial
CSJ Probert et al.
GUT (2003)
分享论文
